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The use of complementary and alternative medicine and herbal products, especially traditional Chinese medicines,
is progressively rising for both adults and children. This increased use is based on the popular belief that these
medicines are safe and harmless. In this report, we describe the results of a bedside-to-bench study that
involved a short-statured 4-year-old boy with deficiencies in growth hormone, thyroid stimulating hormone,
and adrenocorticotropic hormone due to an ectopic posterior pituitary gland and invisible pituitary stalk. Although
the boy was given replacement therapy with hydrocortisone and L-thyroxin, the parents refused to treat him with
growth hormone and consulted a naturopath who prescribed a traditional Chinese medicine (TCM) to stimulate
the boy’s growth. From the age of 20 months, the child’s growth was regularly monitored while he was being
treated with hydrocortisone, thyroxin, and the TCM. Over a 36-month period, the child’s growth velocity accelerated
(3 cm/year to 8 cm/year), his height increment substantially increased (-2 SD to -0.8 SD), and his bones matured.
In the laboratory investigation, estrogen receptor (ER)alpha and ERbeta reporter cell lines were used to characterize
the estrogenic activity of the TCM medicine and its 18 components, and the results established that the medicine
and some of its components have estrogen receptor ERalpha and ERbeta selectivity and partial estrogen agonism.
Partial estrogenic activity of the TCM was confirmed using whole-cell competitive binding, cell proliferation, and
endogenous gene expression assays in the ERalpha-positive breast cancer cell lines. Although the presence of
evidence is not always evidence of causality, we have concluded that this traditional Chinese medicine contains
ingredients with estrogenic activity that can sustain bone growth and maturation without affecting other
estrogen-dependent tissues.
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Over the past few decades, the use of traditional Chinese
medicines (TCMs) has become internationalized. Although
most components in TCMs are derived from plants, some
are also derived from animals. Irrespective of the source of
their components, TCMs are generally perceived as being
safe and easy to use [1-5].* Correspondence: c-sultan@chu-montpellier.fr
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unless otherwise stated.Our interest in TCMs and their possible effect on
growth began when a short-statured 4-year-old boy with
multiple pituitary hormone deficiencies, whose parents
refused to treat him with growth hormone, exhibited un-
expected growth acceleration and rapid bone maturation
without any untoward effects on the development of his
breast and genitals. On questioning, the boy’s parents
informed us that he was also being treated with a TCM
which had been prescribed by a naturopath. This TCM
comprised 18 different components, of which 16 were
derived from plants.
Many plants have been identified as containing phy-
toestrogens, some of which have also been classified as
selective ER modulators (SERMs) because they havel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a cell-type, tissue-specific, and dose-dependent manner
[6]. We therefore hypothesized that the growth acceler-
ation and bone-age advancement in our patient was due
to the presence of phytoestrogens in the TCM, and that
these phytoestrogens were acting as SERMs.
It is now well known that the human estrogen receptor
(ER) exists as two subtypes, ERα and ERβ, and that the
two subtypes are expressed in the human growth plate.
Both subtypes are ligand-inducible transcription factors,
and their activities are regulated by 17β-estradiol (E2),
which is important for the growth and maintenance of a
diverse range of tissues, such as the mammary gland,
uterus, and bone, and physiological systems like the car-
diovascular and central nervous systems. Specifically,
estrogens have a well-defined critical role in bone mat-
uration and longitudinal bone growth in boys and girls
[7,8], and clinical observations have confirmed the role
of estrogens in regulating longitudinal bone growth and
growth plate closure. Low estradiol levels were shown
to enhance skeletal growth during early sexual matur-
ation (the pubertal growth spurt), while high E2 levels
during late puberty accelerated growth plate fusion and
the cessation of longitudinal bone growth [7,9]. In the
absence of estrogens, as found in females and males
with a mutation of the aromatase gene or in the presence
of a mutation of the ERα gene, the duration of the puber-
tal growth spurt is prolonged and the affected individuals
continue to grow slowly after sexual maturation because
the growth plates do not fuse [8,10,11]. Furthermore, in
some patients with growth hormone deficiency and
advanced puberty, the pubertal growth spurt is observed,
suggesting that estrogens may act directly on growth plate
chondrocytes [12].
The effect of estrogens on target tissues depends on
the balance between ERα and ERβ signaling [13] and, in
phytoestrogens, on the varying degrees of selectivity for
ERα and ERβ [14]. The expression of ERα and ERβ in
the human growth plate, with no difference in the expres-
sion pattern over the course of puberty or between sexes,
reinforces the idea that estrogens can influence growth
plate chondrocytes [15].
It is known that ER contains two distinct and inde-
pendent transcriptional activation functions, AF-1 and
AF-2 [16]. The activity of AF-1, which is located at the
N-terminal A/B region of the receptor, is constitutive,
whereas the activity of AF-2, which is located at the
COOH terminus in the hormone-binding domain, is
estrogen-inducible. Full transcriptional activity of the ER
is achieved through synergism between its AFs [17]. It has
also been reported that AF-1 possesses strong ligand-
independent activity in some cell types and on some
promoters and that the partial agonist activity of the
ER can be modulated by the activity of AF-1 [18]. Theamino acids (aa) that are important for AF-1 activity
are found in segments between aa 41 and 120–150 at
the N-terminal A/B region of the receptor [19]. The
molecular mechanism of estrogen action on growth
plate closure has recently been clarified. Growth plate
closure only occurs in mice following specific inactiva-
tion of AF-1 in the ERα. This finding indicates that
growth plate closure is induced by functions of the
ERα that do not require AF-1 and that ERα AF-1 op-
poses growth plate closure [20]. The role of ERβ in
growth plate cartilage seems more questionable in
males [21] since knocking out ERβ in male mice does
not influence bone growth at any stage of their deve-
lopment [22-24].
In order to test our hypothesis, we undertook a study
to determine whether any of the 18 components in the
TCM possess ERα or ERβ activity. To this end, we de-
termined the estrogenic potencies of the TCM and
each of the 18 components using estrogen-responsive
element (ERE)-based luciferase reporter ERα and the
ERβ assays. Furthermore, we confirmed that the TCM
had estrogenic activity using binding assays, endogen-
ous E2-regulated genes expression and E2-regulated
proliferation assays in an ERα − positive breast cancer
MCF-7 cell line.
Case report
The boy was born after an uneventful pregnancy at 37
weeks gestation with a birth weight of 2,910 grams and
is the first child of healthy non-consanguineous parents.
The clinical examination at birth revealed a severe
micropenis (1 cm, <2.5 SDS) and bilateral undescended
testes, and the results of clinical endocrinology exam-
ination revealed signs of neonatal hypoglycemia, central
hypothyroidism, and growth hormone (GH) and adreno-
corticotrophic hormone (ACTH) deficiencies (Table 1).
Replacement therapy with hydrocortisone (8 mg/m2 BSA)
and 50 μg/day L-thyroxin was initiated. The bone age
of the child before the start of replacement therapy
was 3 years and the results of a brain magnetic reson-
ance imaging (MRI) study revealed an ectopic poster-
ior pituitary gland and an invisible pituitary stalk. The
parents refused the recommended GH replacement
therapy and consulted a naturopath, who prescribed a
TCM with 18 components, of which 16 were of plant
origin and two were of animal origin (Table 2). In
addition to the hydrocortisone and thyroxin, the child
was treated with the TCM (2-4 mls/day per os) for 36
months, during which his growth was regularly moni-
tored. Over this 36-month period, his growth velocity
accelerated (3 cm/year to 8 cm/year), his SD score for
height substantially increased (-2 to -0.8), and his bone
age advanced to 7 years. No changes were noted in the
development of his breasts or genitals.
Table 1 Results of endocrine evaluation in the neonatal period and the growth hormone axis at different ages
Neonatal period Basal Stimulated
/ ACTH
Cortisol (nmol/l) 20 (N > 300) 25 (N > 500)
TSH (mU/l) 5 (N:0.7 – 15)
TT4 (μg/dl) 4 (N > 5)
GH (μU/ml) during hypoglycemia 8.2 (N > 20)
20 Months / Arginine
GH (μU/ml) 2.4




IGF1 (nmol/l) 5.3 (N: 6.6-42.5)
52 Months
IGF1 (nmol/l 16 (N:5.7-26.4).
X’: time in minutes.
/ ACTH” serum cortisol level after stimulation testing with ACTH after 60 minutes.
TSH: thyroid-stimulating hormone.
TT4: total thyroxine.
/ Arginine: serum GH level after stimulation testing with arginine.
IGF-1: insulin-like growth factor 1.
Table 2 The 18 components of the traditional Chinese medicine
Botanical, zoological or pharmaceutical name Pinyin transliteration Amount in medicine (grams) Identification code
Polygonatum sibiricum Redoute huang jing 5 A
Astragalus membranaceus (Fisch.) Bge huang qi 5 B
Drynaria fortunei (Kunz) J. Sm gu sui bu 5 C
Boswellia carterii Birdw. ru xiang 5 D
Cervus nippon Temmiinck lu rong 5 E
Gallus gallus domesticus Brisson ji nei jin 5 F
Morinda officinalis How bai ji li 5 G
Ophiopogon japonicus Ker-Gawl mai men dong 5 H
Commiphora myrrha Engl. mo yao 5 I
Rehmannia glutinosa (Gaertn.) Libosch shu di 5 J
Dioscorea opposita Thunb. shan yao 6 K
Cornus officinalis Sieb. et Zucc. shan zhu yu 5 L
Bupleurum chinense D.C. chai hu 4 M
Alisma plantago-aquatica L.var. orientale Samuels ze xie 3 N
Massa Ferentata Medicinalis shen qu 2 O
Glycyrrhiza uralensis Fischer gan cao 10 P
Poria cocos (Schw.) Wolf fu ling 5 Q
Citrus reticulata Blanco chen pi 5 R
Sixteen of the components are of plant origin and two of the components, lu rong (E) and ji nei jin (F) are of animal origin. Massa fermenta medicinalis (O) is a
non-standardized mixture of a fermented preparation of wheat flour and bran and the fresh aerial parts of medicinal herbs that may include xanthium, apricot
kernel, artemesia, polygonum, and phaseolus.
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Chemicals, reagents, and preparation of tinctures
Dulbecco’s modified Eagle medium: Nutrient Mixture F12
(DMEM F12), fetal calf serum (FCS) and geneticin, were
purchased from Life Technologies Inc., Cergy-Pontoise, France.
Luciferin was purchased from Promega, Charbonnières,
France. E2, genistein, ferutinin, puromycin, and 3-[4,5-
dimethyliazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
were purchased from Sigma-Aldrich, Inc., St. Louis, MO,
USA.
Ethanol tinctures (35%) of each component in the
TCM (A-R) (Table 2) were prepared in the following
manner. After weighing, each component was first minced
with a surgical scalpel and then dissolved in 70% ethanol:
30% sterile water at a solvent to plant ratio of 3:1 (v/w).
Each solution was then steeped at room temperature for 3
weeks on a horizontal agitator, and then filtered through
sterilized tulle. The filtrate was then diluted in sterile
water at a ratio of 2:1 (v/v) in order to obtain a 35%
ethanol tincture.
Stock solutions (10 nM in DMSO) of E2, genistein,
and ferutinin were stored at -20°C. The TCM and the 18
tinctures were stored at 4°C. Before each assay, the stock
solutions, the TCM, and the 18 tinctures were serially
diluted using culture medium.
Determination of ER Activity of the herbal medicine and
its components
ERE-luciferase reporter assays were done in reporter
HELN-ER cell lines [25] to investigate whether the TCM
and any of its components have ER activity. Briefly, these
cells were generated in two steps. The estrogen-responsive
reporter gene was first stably transfected into HeLa cells,
generating HELN cell line (named HELN for HeLa-
ERE-Luciferase-Neo) and, in a second step, these HELN
cells were transfected with ERα (amino acids 1-595),
ΔA/B deleted domain ERα (ΔA/B-ERα and amino acids
179-595), ERβ (amino acids 1-530) and ΔA/B-ERβ
(amino acids 143-530) plasmid constructs to obtain the
HELN-ERα, -ΔA/B-ERα, -ERβ, and -ΔA/B-ERβ cell lines,
respectively.
The HELN-ER cells were cultured in DMEM F12
without red phenol, which was supplemented with 5%
dextran-coated charcoal-treated FCS (DCC-FCS), 1%
antibiotic, 1 mg/ml G418, and 0.5 μg/ml puromycin in a
5% CO2 humidified atmosphere at 37°C. For all assays,
the HELN cells were cultured in DMEM, which was
supplemented with 5% FCS and 1% antibiotic, in a 5%
CO2 humidified atmosphere at 37°C.
The TCM and its 18 components were first tested for
non-specific modulation of luciferase expression on the
HELN parental cell line, which contains the same reporter
gene as HELN-ER cells but is devoid of ER. Except for
component P, no toxicity or non-specific modulation wasobserved at concentrations lower than 1%. Then, the TCM
and its components were tested for their ER activity. For
this purpose, HELN and HELN-ER reporter cells (5 × 104
cells/well) were seeded into a 96-well white opaque tissue
culture plate (Greiner reference 655083). Eight hours after
seeding, the cells were then exposed for 16 hours at 37°C to
serial dilutions of the TCM and its 18 components (1%
to 0.0001% of the methanol extract). At the end of the
16-hour incubation, the medium that contained the
TCM or the tinctures was removed and replaced by test
culture medium that contained 0.3 mM luciferin. At this
concentration, luciferin diffuses into the cells, which
generate a “glow-type” luminescent signal that is very
stable for several hours. This luminescence was mea-
sured for 2 seconds in a MicroBeta Trilux luminometer
(EGG Wallac, Turku, Finland). All assays at each con-
centration or dilution were done in quadruplicate, and
three experiments were done in order to establish the
response curves. The results are expressed as a percent-
age of maximum luciferase activity (100%), which was
obtained in the presence of 10 nM E2. In order to obtain
an indirect measure of the affinity for ERs of the TCM
and its 18 components, the estrogenic potency or the
concentration that yielded the half-maximal luciferase
activity (EC50) of the TCM and its 18 components was
determined.
Whole-cell ERα and ERβ competitive binding assays
HELN-ERα and HELN-ERβ cells were seeded into each
well (7 × 104 cells/well) of a 96-well white opaque
tissue culture plate with a clear bottom (Greiner refer-
ence 655098) and grown in the test culture medium for
24 hours in a 5% CO2 humidified atmosphere. At the
end of the 24 hours, the cells were exposed to increas-
ing dilutions of the TCM (1-0.0003%) in the presence
of 0.3 nM [3H]-E2 (41.3 Ci/mmol specific activity) for 3
hours at 37°C. At the end of the incubation, the liquid
in each well was aspirated and the cells were washed
three times with 100 μl of cold phosphate buffered
saline (PBS). Scintillation fluid (50 μl) (LS-6000-SC,
Beckman-Coulter, Roissy, France) was added to each
well, and the amount of [3H]-bound radioactivity in
the mixture was determined using the MicroBeta
Trilux luminometer (EGG Wallac, Turku, Finland).
Non-specific binding was determined in the presence
of 100 nM unlabeled E2. Specific binding was calcu-
lated by subtracting non-specific binding from total
binding and was expressed as a percentage of the
maximum ER binding (100%), which was obtained in
absence of the herbal medicine. The IC50 value was
defined as the dilution at which [3H]-E2 binding was
50%. Determinations were made in quadruplicate in
three separate experiments. The absence of toxicity
was determined by visual inspection.
Tiosano et al. Reproductive Biology and Endocrinology 2014, 12:97 Page 5 of 14
http://www.rbej.com/content/12/1/97MCF-7 cell proliferation assay
MCF-7 cells were seeded into each well (103 cells/well) of a
96-well culture plate and grown in the test culture medium
for 24 hours at 37°C. After 24 hours, the cells were exposed
for 6 days at 37°C in a 5% CO2 humidified atmosphere




Figure 1 The concentration-response curves to E2 (a), genistein (b), a
(ERα), HELN-ERβ (ERβ), HELN-ΔA/BERα (ΔAB-ERα), and HELN-ΔA/BERβ (ΔAB
for 16 hours at 37°C in a 5% CO2 humidified atmosphere. The results are ex
was determined when the cells were exposed to 10−8M E2. Each value at e
deviation from three separate experiments.increasing dilutions of the TCM (1-0.001%). At the end
of the incubation period, the medium in each well was
removed and replaced by 100 μl of test culture medium
that contained 0.5 mg/ml 3-(4,5-methylthiazol-2yl)-2,5-
diphenyltetrazolium bromide (MTT). At the end of a 4-
hour incubation at 37°C, the MTT-formazan-containingnd ferutinin (c). The curves were constructed by exposing HELN-ERα
-ERβ) cells to increasing concentrations of E2, genistein, and ferutinin
pressed as a percentage of maximum luciferase activity (100%), which
ach concentration in the response curves is the mean ± standard
Table 3 EC50 of 17β estradiol (E2); the phyotoestogen, genistein; the sesquiterpenoid, ferutinin; the traditional Chinese
medicine (TCM); and the six selected components of the herbal medicine that were determined in the HELN-ERα,
HELN-ERβ, HELN-ΔA/BERα, and HELN-ΔA/BERβ cell lines
ERα ΔΑ/ΒERα ERβ ΔΑ/ΒERβ ERα vs ERβ
p-value
EC50 (nM)
E2 0.017 0.034 0.068 0.22
Genistein 18.8 49.4 6.1 18.8
Ferutinin 0.64 0.65 3.9
EC50 (%)
Traditional Chinese medicine 0.035 0.055 0.015 0.035 0.015
B 0.2 0.25 0.055 0.15 0.003
F 0.2 0.2 0.03 0.1 <0.001
J 0.04 0.04 0.02 0.03 NS
L 0.3 0.3 0.4 0.4 NS
P 0.004 0.007 0.002 0.004 NS
R 0.07 0.08 0.035 0.06 NS
The EC50 values for E2, genistein, and ferutinin are expressed in nM, whereas those of the TCM and the components are expressed as percentages and correspond
to dilutions of the TCM or components (1% = 100-fold dilution). Significant p-values corresponding to Student's t-test are reported (NS: not significant at the 5%
significance level).
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formazan crystals were dissolved by adding 100 μl
DMSO. After shaking, the cell number in each well
was determined from the absorbance of the solution,
which was measured with a microplate spectropho-
tometer at an absorbance of 540 nm. Wells that con-
tained only the test culture medium and MTT were
used to blank the plate reader. Determinations were
made in quadruplicate, and the data are expressed as
the average absorbance of four wells at each concentra-
tion or dilution in three separate experiments. The
results are expressed as a percentage of maximumTable 4 Maximal transcriptional activity of 17β estradiol (E2);
ferutinin; the traditional Chinese medicine (TCM); and the six
determined in the HELN-ERα, HELN-ERβ, HELN-ΔA/BERα, and
ERα ΔΑ/ΒERα ERα




Traditional Chinese medicine 107.4 58 0.0
B 80 39.6 NS
F 94 57 0.0
J 78 29 NS
L 69 23 NS
P 111 70 0.0
R 85 33 0.0
Significant p-values corresponding to Student’s t-test are reported (NS: not significaluciferase activity (100%), which was obtained the pres-
ence of 10 nM E2.
E2-induced gene expression assays
The effect of the TCM on endogenous estrogen-regulated
gene expression was assessed by determining the mRNA
levels of GREB1, pS2, RIP140, RARα and PR in MCF-7
cells using RT-PCR. For this purpose, MCF-7 cells were
treated for 24 hours with either 10 nM E2 or a 0.3% dilu-
tion of the TCM. At the end of the treatment, RNA was
extracted from the cells using the RNeasy RNA isolation
kit (Qiagen, Courtaboeuf, France). For RNA extractions,the phyotoestogen, genistein; the sesquiterpenoid,
selected components of the herbal medicine that were
HELN-ΔA/BERβ cell lines
vs ΔΑ/ΒERα ERβ ΔΑ/ΒERβ ERβ vs ΔΑ/ΒERβ




14 78 56 <0.001
100 50 0.021
02 86.5 53 <0.001
61 35 NS
49 16 NS
21 92 73 NS
04 35 19 NS
nt at the 5% significance level).
Figure 2 The dilution-response curves to the traditional Chinese
medicine (TCM). The curves were constructed by exposing HELN-ERα
(ERα), HELN-ERβ (ERβ), HELN-ΔA/BERα (ΔAB-ERα), and HELN-ΔA/BERβ
(ΔAB-ERβ) cells to increasing dilutions of the TCM for 16 hours at 37°C
in a 5% CO2 humidified atmosphere. The results are expressed as a
percentage of maximum luciferase activity (100%), which was
determined when the cells were exposed to 10−8M E2. Each value
at each dilution in the response curves is the mean ± standard
deviation from three separate experiments. p < 0.05: * = EC50 ERα vs
ERβ, ** = Max. luciferase activity ERα vs ΔA/B ERα, *** = Max
luciferase activity ERβ vs ΔA/B ERβ.
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Reverse transcription was done on 1 μg total RNA using
random hexamers and SuperScript™ II reverse transcript-
ase (Invitrogen) in a reaction solution which was diluted
ten times for amplification. The mRNA levels of GREB1,
pS2, RIP140, RARα, and PR were quantified by RT-PCR
using SYBR® Green reagents in a LightCycler® RT-PCR
System (Roche SAS, Boulogne-Billancourt, France). The
expression levels of each gene were normalized to that of
the housekeeping 28S gene, and quantified in relative
units using qBasePLUS [26]. Determinations were made in
duplicate.
Data analysis
Data are reported as mean ± standard deviation or stand-
ard error of the mean. The response curves were fitted
and analyzed using the sigmoid dose-response function of
a computerized graphics and statistics software package
(Graph-Pad Prism, version 4.0, 2003, Graph-Pad Software
Inc., San Diego, CA, USA).
The dose-response curves were fitted using a four-
parameter log-logistic model. Statistical comparisons
between parameters of fitted curves (EC50 and maximalTable 5 The EC50 and maximal transcriptional activity of the traditional Chinese medicine (TCM) and its 18 components
that were determined in the HELN-ERα and HELN-ERβ cell lines
ERα ERβ
Max. luciferase activity % EC50 % Max. luciferase activity % EC50 %
Traditional Chinese medicine 107.4 0.035 78 0.015
Huang Jing A 48 51
Huang Qi B 80 0.2 100 0.055
Gu Sai Bu C 34 23
Ru Xiang D 38 23
Lu Rong E 74 33
Ji Nei Jin F 94 0.2 86.5 0.03
Bai Ji Li G 44 33
Mai Men Dong H 93 38
Mo Yao I 43 0.009 37 0.004
Shu Di J 78 0.04 61 0.02
Shan yao K 73 45
Shan Zu Yu L 69 0.3 49 0.4
Chai Hu M 57 0.1 43 0.1
Ze Xie N 33 20
Shen Qu O 100 61
Gan Cao P 111 0.004 92 0.002
Fu Ling Q 108 45
Chen Pi R 85 0.07 35 0.035
The EC50 values of the herbal medicine and the 18 components are expressed as percentages and correspond to dilutions of the TCM or component (1% = 100-fold
dilution). The percentage of maximum luciferase activity (100%) was determined when the cells were exposed to 10−8M E2. The complete identification code of the 18
herbal components is explained in Table 2.
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software (R Development Core Team 2013: [27]). One-
way ANOVA and Tukey's multiple comparison tests
were performed to compare the effect of TCM on gene
expression of the estrogen receptor versus E2 and a
control. Statistical significance was set at 5%.Figure 3 The dilution-response curves to components B, F, J. The curv
HELN-DA/BERα (DAB-ERα), and HELN-DA/BERβ (DAB-ERβ) cells to increasing
37°C in a 5% CO2 humidified atmosphere. The results are expressed as a perc
when the cells were exposed to 10-8M E2. Each value at each dilution in the r
experiments. p < 0.05: * = EC50 ERα vs ERβ, ** = Max. luciferase activity ERα vsResults
In order to evaluate the estrogenic activity of the TCM,
we used previously established reporter cell lines [25,28].
These cell lines, which expressed ERα, ERβ or these recep-
tors deleted of their A/B region (ΔA/BERα, ΔA/BERβ),
allowed characterization of ER specificity (between ERαes were constructed by exposing HELN-ERα (ERα), HELN-ERβ (ERβ),
dilutions of ingredient B (a), F (b), J (c) of the TCM for 16 hours at
entage of maximum luciferase activity (100%), which was determined
esponse curves is the mean ± standard deviation from three separate
ΔA/B ERα, *** = Max luciferase activity ERβ vs ΔA/B ERβ.
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ism). Before assessing the estrogenic activity of the
herbal medicine, we used these cell lines to characterize
two phytoestrogens, genistein and ferutinin, in compari-
son with the ER natural ligand, estradiol. Substantial dif-
ferences in maximal activities and EC50s were detected
in the concentration-response curves for E2 (Figure 1a)Figure 4 The dilution-response curves to components L, P, R. The curv
HELN-DA/BERα (DAB-ERα), and HELN-DA/BERβ (DAB-ERβ) cells to increasing
37°C in a 5% CO2 humidified atmosphere. The results are expressed as a perc
when the cells were exposed to 10-8M E2. Each value at each dilution in the r
experiments. p < 0.05: * = EC50 ERα vs ERβ, ** = Max. luciferase activity ERα vsand the phytoestrogens genistein (Figure 1b) and feruti-
nin (Figure 1c). The EC50s for E2 in the HELN-ERα,
HELN-ERβ, HELN-ΔA/BERα, and HELN-ΔA/BERβ cell
lines were 0.017 nM, 0.068 nM, 0.034 nM, and 0.22 nM,
respectively, and these values are in agreement with
previously reported values [25,28]. The EC50 of ERα for
genistein was higher than that of ERβ (Figure 1b andes were constructed by exposing HELN-ERα (ERα), HELN-ERβ (ERβ),
dilutions of ingredient L (a), P (b), R (c) of the TCM for 16 hours at
entage of maximum luciferase activity (100%), which was determined
esponse curves is the mean ± standard deviation from three separate
ΔA/B ERα, *** = Max luciferase activity ERβ vs ΔA/B ERβ.
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than ERα [28]. Interestingly, deletion of the N-terminal
A/B domain of ERβ had a partial effect on genistein’s
transactivation efficacy (115.6 and 77.6% of maximal
activity for ERβ and ΔA/BERβ, respectively) (Table 4),
which confirms previously published findings that genis-
tein is a partial ERβ agonist [29,30]. Ferutinin appeared to
be a full ERα agonist and a partial ERβ agonist (99.1 andFigure 5 The effect of the traditional herbal medicine (TCM) on E2 bin
curves for ERα (a) and ERβ (b) were generated by exposing HELN-ERα and HEL
the presence of radiolabeled 17β-estradiol (E2) (0.3 nM [3H]-E2) for 3 hours
was expressed as a percentage of the maximum ER binding (100%), which
The IC50 value was defined as the dilution at which E2 binding was 50%. E
duplicate determination ± standard deviation from three separate experim38.8% of maximal activity for ERα and ERβ, respectively)
(Table 4). Moreover, ferutinin lost its partial activity
when the N-terminal A/B domain of ERβ was deleted
(Figure 1c).
We then tested the estrogenic activity of the TCM and
its 18 components. The EC50s for ERα and ERβ and the
maximal activity are summarized in Tables 3, 4 and 5.
The EC50 for ERβ of the TCM was slightly lower thanding to estrogen receptor (ER)α and ERβ. Τhe competition binding
N-ERβ cells, respectively, to increasing dilutions of the TCM (1%-0.0003%) in
at 37°C in a 5% CO2 humidified atmosphere. The amount of binding
was defined when the cells were exposed to 100 nM unlabeled E2.
ach value at each dilution in the binding curves is the mean of
ents. * = p < 0.05 for IC50 ERα vs ERβ.
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http://www.rbej.com/content/12/1/97that of ERα (0.015% versus 0.035%) (p = 0.015). All the
18 components were found to have estrogenic activity
and we were able to determine the EC50s for ERα and
ERβ s for eight components, namely B, F, I, J, L, M, P,
and R (Table 5). The EC50s for ERβ of the TCM and four
of its components, I, J, P, and R, were slightly lower than
those for ERα, but not significantly at the 5% significance
level. The EC50s of two components for ERβ (B and F)
were significantly lower than those for ERα (p = 0.003 and
p < 0.001, respectively). The EC50s for ERα and ERβ of the
remaining two components, L, and M, were very similar
(Table 3).
The HELN-ΔA/BERα and HELN-ΔA/BERβ cell lines
were then used to further characterize the agonistic
properties of the TCM and six of the eight components,
which presented the maximal transcriptional activity on
ERs (Table 4, Figures 2, 3 and 4). We found that the
maximal activity values of the TCM and the six selected
components in the HELN-ΔA/BERβ and HELN-ΔA/BERα
cells were always lower than those found in the HELN-ERα
and HELN-ERβ cells (Table 4). For example, we found that
the maximal activity of the TCM in the HELN-ERα cells
was 107.4% versus 58% (p = 0.014) in the HELN-ΔA/BERα
cells. This finding was confirmed in HELN-ERβ and
HELN-ΔA/BERβ cells: the maximal activity of the TCM
in the HELN-ERβ cells was 78% versus 56% (p = 0.026) in
the HELN-ΔA/BERβ cells. This result suggests that the
TCM and the six selected components have partial ER
agonist activity.
We then characterized the estrogenic activity of the
TCM. Whole-cell ER competitive binding assays using
[3H] E2 binding to ERα and ERβ were then done in
order to confirm that the ER activity of the TCM is
achieved by binding to ERα and ERβ. The IC50 for ERβ
of the TCM was 0.1% and this value was slightly lower
than its IC50 for ERα, 0.3% (p < 0.05). This finding alsoFigure 6 The proliferative response of MELN cells to the traditional C
exposing HELN cells to increasing concentrations of E2 (10
−13M – 10−8 M) a
to the vital mitochondrial dye, 3-[4,5-dimethyliazol-2-yl]-2,5-diphenyltetrazo
atmosphere. The data are expressed as a percentage of the maximum prol
when the cells were exposed to 10−8M 17β-estradiol. Each value at each co
determinations ± standard deviation from three separate experiments.confirms that the binding affinity for ERβ of the TCM
was slightly greater than that for ERα (Figure 5).
We then determined whether the TCM was able to
activate endogenous E2-regulated genes in the ERα+
breast cancer cell line MCF-7. For HELN cell prolifera-
tion, we first found that the medicine acted as a full
agonist on cell growth and that cell proliferation began
to be activated at 0.003% (Figure 6). We also found that
the TCM medicine was able to activate the expression
of the endogenous E2-regulated genes, namely pS2, PR,
RIP140, RARα, and GREB1 (Figure 7). This was statis-
tically significant at the 5% significance level for pS2,
RIP140 and RARα.
Discussion
The billowing use of alternative medicines and in par-
ticular herbal products and TCMs by adults and children
[31] is based on the popular belief that these products
are “harmless.” Based on the knowledge that there are
numerous estrogens with varying degrees of selectivity
for ERα and ERβ in many TCMs [14], we hypothesized
that the TCM, which was prescribed by a naturopath to
a short-statured 4-year-old boy with multiple pituitary
hormone deficiencies, would contain components with
potent estrogen activity and would be responsible for
the child's growth acceleration and bone maturation.
In order to test this hypothesis, we investigated the
estrogenic activity of the TCM and its 18 components
in a chemistry-focused study and a target-directed
study. In the chemistry-focused study, we investigated
the estrogenic activity of the TCM and its 18 compo-
nents and found that the TCM and its components
possess partial ERβ and ERα agonist activity with a
slightly higher affinity for ERβ. In the target-directed
study, we investigated the mechanism of action of the TCM
constituents using reporter HELN-ERβ and ERα-positivehinese medicine (TCM). The proliferation curves were generated by
nd increasing dilutions of the TCM (1% - 0.001%) for 10 days, and then
lium bromide (MTT), for four hours at 37°C in a 5% CO2 humidified
iferation (100%), which was defined as the amount of proliferation
ncentration or dilution in the curves is the mean of quadruplicate
Figure 7 The effect of the traditional Chinese medicine (TCM) on gene expression of the estrogen receptor. MELN cells were treated for
24 hours at 37°C in a 5% CO2 humidified atmosphere with either 10
−8M 17β-estradiol (E2) or a 0.3% dilution of the TCM. At the end of the incubation,
the mRNA expression levels of five endogenous E2-regulated genes, pS2, the progesterone receptor (PR) , RIP140 , GREB1 , and RARα , were
determined by quantitative real-time polymerase reaction. The expression levels of each gene were normalized to that of the housekeeping
28S gene, and quantified in relative units using qBase PLUS [26]. Data are displayed as the average of two determinations ± standard error of
the mean. * = p < 0.05 vs ETOH.
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http://www.rbej.com/content/12/1/97cell lines and confirmed partial estrogenic activity using
whole-cell competitive binding, cell proliferation, and
endogenous gene expression assays. From these results,
we have concluded that the TCM contains compounds
that could be considered to be potential selective estro-
gen receptor modulators (SERMs) with specific agonist
estrogenic activity.
A recent work demonstrated the stimulating action of
a phyto-SERM, resveratrol, on growth plate cartilage
[32]. This phyto-SERM displayed E2 antagonist activity
for ERα with selected EREs and agonist activity for ERβ
[33]. In rabbits, resveratrol improves both axial and appen-
dicular bone growth without altering the serum insulin-likegrowth factor-1 (IGF-1) level [32]. Nevertheless, ERα and
ERβ (activity) may also have a direct action on IGF-1 gene
expression [34] and IGF-1-induced responses [35]. It is thus
possible that the estrogenic actions of some of the TCM
components influenced the serum IGF-1 levels in our study
patient.
Did we prove this hypothesis in this bedside-to-bench
study? We found that the TCM and some of its compo-
nents have ERα and ERβ selectivity and partial estrogen
agonism. Accordingly, we concluded that the complex
estrogenic activity of this TCM was due to the presence
of ingredients with estrogenic activity that are able to
sustain bone growth and maturation without affecting
Tiosano et al. Reproductive Biology and Endocrinology 2014, 12:97 Page 13 of 14
http://www.rbej.com/content/12/1/97other estrogen-dependent tissues. The well-known dom-
inant negative effect of ERβ on ERα, as well as the
partial and AF-1-dependent agonist activity of the TCM,
may explain the absence of breast development in this
patient [36].
Conclusions
This study has several limitations. The first limitation is
the dilution of the phytoestrogens in the various assays that
were used to establish the pharmacological profile for the
estrogenic activity of the TCM and the resultant circulating
phytoestrogen levels in the patient. The TCM was taken
orally by the patient, and we can assume that the serum
and/or tissue concentrations of the TCM and its constitu-
ents would be lower than those in the TCM. Although we
investigated a range of dilutions of the TCM and its
constituents, we found that six of these components have
partial estrogenic activity. The exact phytochemical and
pharmacological profiles of the components are still un-
known, and many drugs are converted to metabolites that
retain the intrinsic activity of the parent drug. This lack of
knowledge is a second limitation of our study. We are not
aware of any studies in which a phytochemical profile of
the ingredients in the TCM has been correlated with an
in vitro and/or in vivo pharmacodynamic profile for phy-
toestogenic activity or a pharmacokinetic profile for the
parent ingredients and their metabolites. The third limita-
tion of our study is the quality and/or purity of the medi-
cine’s components and the method of preparing the TCM.
In this bedside-to-bench study, we found that the TCM
and some of the components had varying estrogenic activ-
ity and potency over a large dilution range. Finally, we did
not use cultured osteoblasts to investigate the estrogenic
activity and mechanism of action of the TCM and its 18
components. Although it is tempting to conclude that the
complex estrogenic activity of the TCM that was given to
our patient accounted for unexpected growth acceleration
and rapid bone maturation without any untoward effects
on the development of his breast and genitals, the finding
of accelerated growth velocity after ingestion of the TCM
could be viewed as coincidental because the TCM is a
non-standardized mixture of 18 components and causality
cannot be unequivocally proved. Although the presence of
evidence is not always evidence of causality, the challenge
now is to identify those constituents in the TCM that may
be therapeutically beneficial for growth-deficient children
and then to develop them as therapeutic agents for these
individuals.
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